Cefixime


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult: PO 200-400 mg/day as a single or in 2 divided doses for 7-14 days depending on the severity of infection.
Administration
May be taken with or without food. May be taken w/ food or milk to reduce GI discomfort.
Contraindications
Hypersensitivity to cephalosporins, penicillins or any beta-lactam antibiotics. Premature and newborn infants.
Special Precautions
Patient with history of cephalosporin-associated haemolytic anaemia, gastrointestinal disease, hypersensitivity to penicillins and other beta-lactam antibiotics. Renal impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause confusion, impaired coordination, movement disorders and convulsions as side effects, if affected, do not drive or operate machinery. Monitoring Parameters Monitor CBC, LFT and renal function periodically for prolonged treatment. Monitor signs and symptoms of anaphylaxis during 1st dose. Perform culture/sensitivity tests and allergy history prior to treatment initiation.
Adverse Reactions
Significant: Encephalopathy including convulsions, confusion, impaired consciousness, and movement disorders (in patient with renal impairment); bacterial or fungal superinfection, decreased prothrombin activity. Blood and lymphatic system disorders: Neutropenia, thrombocytosis, leucopenia, thrombocytopenia, eosinophilia. Gastrointestinal disorders: Diarrhoea, abdominal pain, dyspepsia, flatulence, nausea, vomiting. General disorders and administration site conditions: Pyrexia, face oedema. Hepatobiliary disorders: Jaundice, hepatitis. Immune system disorders: Serum sickness-like reaction, urticaria, angioedema. Investigations: Increased LFTs; elevated BUN, serum bilirubin and creatinine. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Arthralgia. Nervous system disorders: Headache, dizziness, vertigo. Reproductive system and breast disorders: Vaginitis, genital pruritus. Respiratory, thoracic and mediastinal disorders: Dyspnoea. Skin and subcutaneous tissue disorders: Rash, pruritus.
Potentially Fatal: Drug-induced haemolytic anaemia, acute renal failure including tubulointerstitial nephritis, Clostridium difficile-associated diarrhoea, pseudomembranous colitis, severe cutaneous reactions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS); anaphylactic/anaphylactoid reactions including shock.
Drug Interactions
May increase prothrombin time with or without bleeding and enhance effects of anticoagulants (e.g. warfarin K). Increased bioavailability for up to 70% with nifedipine. Increased serum concentration with probenecid. May elevate plasma concentrations of carbamazepine.
CIMS Class
ATC Classification
J01DD08 - cefixime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on cefixime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in